Matinas Biopharma Holdings Inc's Comment on Sales, Marketing and Customers
The company operates within regulatory frameworks that impact customers billing federal programs, including Medicaid and Medicare. It is influenced by federal and state healthcare programs and reforms, such as the Affordable Care Act (ACA). Additionally, the company is affected by legislation promoting the development of antibacterial and antifungal drug products for serious infections, specifically the Generating Antibiotic Incentives Now Act (GAIN Act) and Qualified Infectious Disease Products (QIDP).
News about Matinas Biopharma Holdings Inc Contracts
In an exciting development, the renowned CSIMarket.com is proud to present an exclusive fireside chat hosted by A.G.P., featuring esteemed antifungal expert, Dr. David S. Perlin, and pharmaceutical company Matinas BioPharma. This unique discussion centers around their innovative oral MAT2203 drug and its potential impact on the antifungal treatment landscape. In this article, we will outline the key facts from this influential discussion and assess their implications for Matinas BioPharma.1. MAT2203 - A Game-Changing Antifungal Solution:The fireside chat underscores the significance of Oral MAT2203, a cutting-edge drug developed by Matinas BioPharma. This novel drug holds immense promise in delivering effe...
This article aims to provide an overview of the positive outcomes reported by Matinas BioPharma on their MAT2203 Compassionate/Expanded Use Access Program. The program enrolled 19 patients with serious and life-threatening invasive fungal infections, encompassing a range of fungal pathogens. Additionally, the company has also made progress towards regulatory approval, as indicated by their feedback from the FDA regarding the Phase 3 Registration Trial for MAT2203.Overview of MAT2203 Compassionate/Expanded Use Access Program:The MAT2203 Compassionate/Expanded Use Access Program conducted by Matinas BioPharma has displayed encouraging outcomes in the treatment of various invasive fungal infections. The progra...
Matinas BioPharma, a clinical-stage biopharmaceutical company, has recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) for a single Phase 3 registration trial to support the New Drug Application (NDA) for its drug candidate MAT2203. This agreement is a significant milestone in the development of MAT2203 for the treatment of invasive aspergillosis.The ORALTO Phase 3 trial will focus on the desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options. Invasive aspergillosis is a severe fungal infection that primarily affects immunocompromised individuals, ...
In an exciting development for Matinas BioPharma, the company recently received written preliminary comments from the Food and Drug Administration (FDA) on the Phase 3 registration trial for its leading drug candidate, MAT2203. The feedback moves the company closer to full alignment with FDA expectations, representing a significant milestone in the drug s regulatory and development pathway.Matinas BioPharma is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for serious and life-threatening infections. MAT2203, the company s lead product candidate, is a promising antifungal treatment being developed for patients suffering from invasive candidiasis, a poten...
Matinas Biopharma Holdings Inc’s Comment on Sales, Marketing and Customers
The company operates within regulatory frameworks that impact customers billing federal programs, including Medicaid and Medicare. It is influenced by federal and state healthcare programs and reforms, such as the Affordable Care Act (ACA). Additionally, the company is affected by legislation promoting the development of antibacterial and antifungal drug products for serious infections, specifically the Generating Antibiotic Incentives Now Act (GAIN Act) and Qualified Infectious Disease Products (QIDP).
Sources:
Matinas Biopharma Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Matinas Biopharma Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Matinas Biopharma Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
